Debate Grows Over EMA's Decision on Data Transparency - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Debate Grows Over EMA's Decision on Data Transparency

Source: Applied Clinical Trials

Despite some setbacks, great strides have been made in the past three years towards clinical trial transparency, but a great deal of information still remains hidden from policymakers, clinicians, and patients, and if the European Medicines Agency (EMA) also stops releasing data on old trials, everybody will be kept even more in the dark, according to an editorial posted by bmj.com on May 28.

EMA’s management board is due to meet on June 12 to finalize the policy, and some observers have expressed concern over recent weeks that the Agency has decided to backtrack on its decision for public access to clinical trial data.

On the plus side, even with a “watered down policy”, EMA will be making visible vast quantities of new regulatory information about randomized controlled trials of drugs and other types of interventional or observational clinical research methodologies, noted the BMJ’s Head of Research, Trish Groves, and European Research Editor, Wim Weber.

However, if the new European policies for proactive disclosure close the EMA window that has been allowing ad hoc retroactive access to older clinical study reports and data, then decision-makers will be even less well informed when making decisions about current treatments, they noted.

“That is why AllTrials continues to campaign for all clinical trials to be registered and all results reported. The research, advocacy, haggling, and politics must go on,” the authors wrote.

Read the full release here.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here